Rifapentine Access in Europe: Growing Concerns over Key Tuberculosis Treatment Component

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2022 May 19

PMID 35589114

Authors

Lorenzo Guglielmetti

Gunar Gunther

Claude Leu

Daniela Cirillo

Raquel Duarte

Alberto L Garcia-Basteiro

Delia Goletti

Mateja Jankovic

Liga Kuksa

Florian P Maurer

Frederic Mechai

Simon Tiberi

Frank van Leth

Nicolas Veziris

Christoph Lange

Affiliations

Soon will be listed here.

Citing Articles

TB prevention activities in the WHO European Region.

Matteelli A, Mkrtchyan Z, Masini T, Hovhannesyan A, Kuchukhidze G, Ahmedov S IJTLD Open. 2024; 1(8):349-354.

PMID: 39131590 PMC: 11308406. DOI: 10.5588/ijtldopen.24.0350.

Conjugated hyperbilirubinemia associated with accidental rifapentine overdose.

Yohane M, Naufal F, Mendoza-Ticona A, Svensson E, Weir I, Scarsi K Int J Tuberc Lung Dis. 2024; 28(7):354-356.

PMID: 38961547 PMC: 11392536. DOI: 10.5588/ijtld.23.0494.

The Challenges of Tuberculosis Management beyond Professional Competence: Insights from Tuberculosis Outbreaks among Ethiopian Immigrants in Israel.

Bishara H, Weiler-Ravell D, Saffouri A, Green M Trop Med Infect Dis. 2024; 9(2).

PMID: 38393118 PMC: 10892168. DOI: 10.3390/tropicalmed9020029.

Tuberculosis in Spain: An opinion paper.

Moreno Guillen S, Rodriguez-Artalejo F, Ruiz-Galiana J, Canton R, De Lucas Ramos P, Garcia-Botella A Rev Esp Quimioter. 2023; 36(6):562-583.

PMID: 37922367 PMC: 10710671. DOI: 10.37201/req/115.2023.

Tuberculosis prevention: current strategies and future directions.

Vasiliu A, Martinez L, Gupta R, Hamada Y, Ness T, Kay A Clin Microbiol Infect. 2023; 30(9):1123-1130.

PMID: 37918510 PMC: 11524220. DOI: 10.1016/j.cmi.2023.10.023.

References

Njie G, Morris S, Yelk Woodruff R, Moro R, Vernon A, Borisov A . Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Am J Prev Med. 2018; 55(2):244-252. PMC: 6097523. DOI: 10.1016/j.amepre.2018.04.030. View

Dorman S, Nahid P, Kurbatova E, Phillips P, Bryant K, Dooley K . Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021; 384(18):1705-1718. PMC: 8282329. DOI: 10.1056/NEJMoa2033400. View

Lange C, KAY A, Mandalakas A . The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there. Int J Tuberc Lung Dis. 2022; 26(2):85-88. PMC: 9296677. DOI: 10.5588/ijtld.21.0736. View

Swindells S, Ramchandani R, Gupta A, Benson C, Leon-Cruz J, Mwelase N . One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019; 380(11):1001-1011. PMC: 6563914. DOI: 10.1056/NEJMoa1806808. View

van Leth F, Brinkmann F, Cirillo D, Dheda K, Duarte R, Guglielmetti L . The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. Eur Respir J. 2019; 53(1). DOI: 10.1183/13993003.02089-2018. View